Did You Have Yourself a Crashy Little Christmas?
Jody Smith may have dodged a holiday bullet this year. She's hoping. Only time will tell. How did you fare?
Discuss the article on the Forums.


Discussion in 'General Treatment' started by SaraM, Feb 20, 2010.

  1. SaraM

    SaraM Senior Member

  2. glenp

    glenp "and this too shall pass"

    Vancouver Canada suburbs
    TY Sarah - it does look interesting. I wonder if it could also help us.
  3. George

    George Guest

    O.K. I'm just going to post it (grins)

    Introduction to Our Platform Technology

    Mitochondria, present in all cells, provide energy for life processes. It is now recognized that mitochondrial dysfunction plays a role in the pathogenesis of several degenerative disorders. Antioxidants are the body's defense against free radicals. Antioxidants block the effects of oxidation, a chemical reaction that combines single electrons with oxygen to generate free radicals, which can attack and destroy cells.

    Antipodean's proprietary targeted lipophilic cation technology prevents oxidative damage by concentrating antioxidants in mitochondria. MitoQ is targeted to mitochondria by covalent attachment to a lipophilic triphenylphosphonium cation. Because of the large mitochondria membrane potential, the cations accumulate within cellular mitochondria up to 1,000 fold, compared to non-targeted antioxidants such as Coenzyme Q or its analogues. This accumulation enables the antioxidant moiety to block lipid peroxidation, and maintain the integrity of the mitochondria membrane by protecting it from oxidative damage.

    Antipodean's lead compound MitoQ (mitoquinone) is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative damage and prevents cell death. Mitochondrial dysfunction underlies a wide range of degenerative diseases, in which oxidative stress plays a key pathogenic role, including such diseases as NASH, Type 2 diabetes, ischemic heart disease, among others. Therefore, protecting mitochondria from oxidative damage is a promising and innovative therapeutic strategy.
    The lipophilic cation is accumulated 5- to 10- fold into the cytoplasm from the extracellular space by the plasma membrane potential and then further accumulated 100- to 500- fold into the mitochondrial matrix by the mitochondrial membrane potential.
    MitoQ is being evaluated as an oral treatment for liver inflammation that leads to fibrosis and is associated with metabolic dysfunction. The company is also investigating topical indications that involve mitochondrial dysfunction, including dermatologic applications and retinal degeneration.

  4. Chris

    Chris Senior Member

    Victoria, BC
    I am a bit late to this, but mitoQ is advertized as available from ProHealth--it is expensive--has anyone tried it yet? Chris
  5. I'm interested too if anyone has tried this yet?

  6. catly

    catly Senior Member

    outside of NYC
    I tried it for 2 months over this past winter. It didn't seem to do anything at all for me. I decided not to reorder due to the expense.
    Little Bluestem and Chris like this.

See more popular forum discussions.

Share This Page